Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 07BANGKOK5644, FDA CHIEF EXPECTS NO MORE CL'S

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #07BANGKOK5644.
Reference ID Created Released Classification Origin
07BANGKOK5644 2007-11-01 09:48 2011-08-25 00:00 UNCLASSIFIED Embassy Bangkok
VZCZCXRO5201
RR RUEHCHI RUEHDT RUEHHM RUEHNH
DE RUEHBK #5644/01 3050948
ZNR UUUUU ZZH
R 010948Z NOV 07
FM AMEMBASSY BANGKOK
TO RUEHC/SECSTATE WASHDC 0461
RUCNASE/ASEAN MEMBER COLLECTIVE
RUCPDOC/USDOC WASHINGTON DC
UNCLAS SECTION 01 OF 02 BANGKOK 005644 
 
SIPDIS 
 
SIPDIS 
 
STATE PASS USTR 
USDOC FOR 4430/EAP/MAC/OKSA 
 
E.O. 12958:N/A 
TAGS: ECON KIPR TH
 
SUBJECT:  FDA CHIEF EXPECTS NO MORE CL'S 
 
1.  Summary:  Dr. Siriwat Tiptaradol, Secretary General of the Thai 
Food and Drug Administration (FDA), said he expected no new 
compulsory licenses on drugs, crediting progress in recent 
discussions with European pharmaceutical companies on pricing and 
access for four cancer drugs.  However, the companies say 
discussions thus far have been preliminary and have not offered any 
concessions.  Ongoing discussions with three companies hit by 
compulsory licenses in the last year have not progressed and the 
Government Pharmaceutical Organization is moving forward with plans 
to import a generic copy of HIV drug Aluvia, nine months after 
announcing a compulsory license.  Thai political parties are vague 
on what position they will hold on the issue after December 
elections.  End Summary. 
 
2.  In a courtesy call by Econ Counselor and Econoff on October 25, 
Dr. Siriwat said he thought there "shouldn't have to be more 
compulsory licenses," but emphasized this was his personal opinion 
and he could not speak for the Ministry of Public Health.  The 
Ministry is considering breaking patents on four cancer drugs 
distributed by three European companies, following on the issuance 
of compulsory licenses on two HIV/AIDS medicines and a heart drug 
over the last year.  The four cancer drugs are distributed by 
Swiss-owned Novartis and Roche, and French-owned Sanofi-Aventis. 
Dr. Siriwat said initial discussions beginning October 18 had gone 
well and companies had responded positively, particularly Roche. 
Siriwat explained the Ministry's long-held position that Thailand's 
public health system was unable to cover the costs for expensive 
life-saving drugs and compulsory licenses were necessary to widen 
access.  He assured that generic versions would be provided only to 
the poor under the RTG's universal health care program.  Dr. Siriwat 
claimed the Thai program "will actually expand the companies' market 
in Thailand," as those who can afford the drugs, such as patrons of 
private hospitals and those with commercial health insurance, will 
still pay the current prices. 
 
3.  Dr. Rolf Ammelburg, Managing Director of Roche Thailand, said 
his initial meeting with the FDA had gone well; the company showed 
its openness to discussion and new proposals, but made no 
commitments.  Ammelburg said the FDA had proposed that Roche lower 
the price of their lung cancer drug erlotinib, submit to a voluntary 
license, or face the possibility of a compulsory license.  The FDA 
did not clearly define how a voluntary license would operate, but 
Ammelburg assumed that the FDA aimed to pursue domestic production 
under license from Roche.  He noted, however, that Thailand may not 
have the domestic capability to produce the drug.  Thailand had 
announced two years ago it would begin generic manufacture of 
another Roche drug, Tamiflu, but has yet to produce a single 
capsule.  Ammelburg felt that the FDA was not anxious to do a 
compulsory license and was strongly pushing the other options to 
avoid such a result. 
 
4.  There has been no further progress in discussions with Merck or 
Abbott, whose patents on antiretrovirals were broken in November 
2006 and January 2007, respectively.  The FDA announced October 17 
that it had approved the registration of a generic version of 
Aluvia, a new heat-stable form of Abbott's AIDS drug Kaletra.  The 
Government Pharmaceutical Organization (GPO) said it would soon 
begin importing the drug from Indian generic manufacturer Matrix 
Laboratories, enough for 8000 HIV-positive patients for six months. 
Matrix offered a price of USD 695 per patient per year, about three 
hundred dollars less than Abbott's listed price. 
 
5.  The FDA appears to have taken a questionable shortcut to approve 
the generic version of Aluvia.  When Thailand issued a compulsory 
license on Kaletra, the older version of the antiretroviral, Abbott 
retaliated by pulling the registration paperwork for the new 
version, Aluvia, which was then only months away from approval. 
Thailand has decided to import generic Aluvia, though its compulsory 
license is actually on Kaletra.  Both drugs share the same chemical 
combination, lopinavir/rotinavir, but it is unclear if the 
compulsory license on the older drug would allow importation of a 
generic version of the new drug.  As well, safety and efficacy data 
required for approval is not on file for Aluvia, and FDA officials 
say they simply accepted the data for Kaletra in its absence.  The 
FDA added a condition to the drug registration that a sample of 
patients would be tested after six months to determine if the 
generic version was effective. 
 
Abbott in the dock 
------------------ 
 
6.  The Thailand Competition Commission is reviewing a complaint 
local public health NGOs have brought against Abbott for its 
decision earlier this March to withdraw the pending registrations of 
seven new drugs, including Aluvia.  The complaint alleges that 
Abbott's action contravenes Section 28 of Thailand's Competition Act 
which forbids restricting opportunities for consumers "to purchase 
goods or services directly from business operators outside the 
 
BANGKOK 00005644  002 OF 002 
 
 
Kingdom."  The Commission is still gathering information about the 
case and has asked Abbott for market share and cost data.  If the 
Commission concludes that Abbott made anti-competitive practices, 
they can recommend the case to a court for a fine or possible 
criminal charges.  Abbott's lawyers say the case probably would not 
meet the Competition Act's criteria for market dominance for 
anti-competitive practices, but are nevertheless concerned that 
local Thai management could be brought up on criminal charges. 
 
Politics isn't over 
------------------- 
 
7.  Political parties vying for election this December are hedging 
on policies on compulsory licenses they might follow if elected.  In 
a forum on access to medicine hosted by public health NGOs, Mr. 
Buranaj Smutharaks, representing the Democrat Party, said his party 
would not obstruct the compulsory licensing process.  Party leader 
Abhisit Vejjajiva had earlier delivered a pro-business message on 
the issue to a business and investor audience, saying he would work 
with the pharmaceutical industry and would use compulsory licenses 
only as a last resort.  However, Buranaj told the health forum that 
"it is highly possible the last resort will get the first priority." 
 Representatives from the People Power Party and Chart Thai party 
told the forum they supported the decision to adopt compulsory 
licenses, but could not commit to how their parties would pursue the 
issue as part of a likely coalition government. 
 
8.  Comment:  Less than two months remain until national elections 
and a thorough change in government, but this is ample time in which 
to implement more compulsory licenses.  Despite Dr. Siriwat's view 
that no more will be necessary, the final decision will be made by 
the Minister of Public Health who may yet use his last days in 
office to push through a last-minute bid for more CLs. 
Post-election, much of the Ministry's top staff will turn over and 
there may be few opportunities in the future to pursue this policy. 
The leading political parties have paid lip service to the current 
policy, but for the most part they are pro-business and would be 
unlikely to pursue compulsory licenses as aggressively as has the 
current government.  End Comment.